Capricor Therapeutics Inc
CAPRHealthcare|Biotechnology|USA
$21.50
-0.99 (-4.40%)
Tangible Book
$4.83
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05126758 A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Muscular Dystrophies, Muscular Dystrophy, Duchenne | P3 | Active | 106 | RCT, Double-blind | Deramiocel (CAP-1002), Placebo |
| NCT04428476 Open-label Extension of the HOPE-2 Trial | Duchenne Muscular Dystrophy | P2 | Active | 13 | Open-label | Deramiocel (CAP-1002) |
| NCT02603614 Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment | Heart Failure, Renal Insufficiency | P1P2 | Completed | 8 | RCT, Double-blind | Cenderitide, Placebo |
| NCT01458405 Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration | Myocardial Infarction | P1P2 | Terminated | 135 | RCT, Double-blind | CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo |
| NCT02359227 Safety Study of Cenderitide in Stable Chronic Heart Failure | Heart Failure | P2 | Completed | 14 | Open-label | Cenderitide |
| NCT04623671 Intravenous Infusion of CAP-1002 in Patients With COVID-19 | Covid19 | P2 | Completed | 55 | RCT, Double-blind | CAP-1002, Placebo |
| NCT06304064 Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) | Duchenne Muscular Dystrophy | P2 | Completed | 8 | Open-label | Allogeneic Cardiosphere-Derived Cells (CAP-1002) |
| NCT02485938 HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) | Duchenne Muscular Dystrophy, Cardiomyopathy | P2 | Completed | 25 | RCT, Open-label | Allogeneic Cardiosphere-Derived Cells (CAP-1002) |
| NCT03406780 A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | Muscular Dystrophies, Muscular Dystrophy, Duchenne | P2 | Completed | 20 | RCT, Double-blind | CAP-1002, Placebo |
| NCT02293603 Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) | Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy | P1 | Unknown | 42 | RCT, Double-blind | Allogeneic Cardiosphere-Derived Cells (CDCs) |
| NCT03680365 Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | Duchenne Muscular Dystrophy, Burden, Dependency | Completed | 60 | — | — | |
| NCT04338347 CAP-1002 in Severe COVID-19 Disease | COVID-19 | NO_LONGER_AVAILABLE | — | — | CAP-1002 Allogeneic Cardiosphere-Derived Cells |